MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-11-2026
Exagen Total Liabilities 2011-2026 | XGN
Annual Total Liabilities Exagen
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 40.6 M | 35.1 M | 34.2 M | 43.8 M | 38.5 M | 36.5 M | 32.7 M | 35.6 M | 25 M | - | 36.8 M | 31.2 M | 16 M | 6.44 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 43.8 M | 6.44 M | 31.7 M |
Quarterly Total Liabilities Exagen
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 37.5 M | 44.7 M | 37.7 M | 33.9 M | 35.1 M | 30.7 M | 31.7 M | 30.8 M | 34.2 M | 33.4 M | 32.3 M | 43.3 M | 43.8 M | 45.4 M | 44 M | 45.9 M | 38.5 M | 37 M | 36.9 M | 36.1 M | 36.5 M | 36.5 M | 36.5 M | 36.5 M | 32.7 M | 32.7 M | 32.7 M | 32.7 M | 35.6 M | 35.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 45.9 M | 30.7 M | 36.7 M |
Total Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
29.7 M | - | -8.98 % | $ 14.8 K |  USA |
 |
Centogene N.V.
CNTG
|
58.6 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Heska Corporation
HSKA
|
164 M | - | - | $ 1.31 B | USA |
 |
Celcuity
CELC
|
366 M | $ 88.28 | -4.53 % | $ 4.13 B | USA |
|
Akumin
AKU
|
1.62 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Co-Diagnostics
CODX
|
4.11 M | $ 5.63 | -2.26 % | $ 7.49 M | USA |
 |
Castle Biosciences
CSTL
|
108 M | $ 21.01 | -2.73 % | $ 609 M | USA |
 |
Fulgent Genetics
FLGT
|
107 M | $ 19.15 | -1.79 % | $ 589 M | USA |
 |
Aspira Women's Health
AWH
|
12.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
84.6 M | - | -61.36 % | $ 2.46 M | USA |
 |
Guardant Health
GH
|
2.11 B | $ 125.61 | -5.6 % | $ 15.7 B | USA |
 |
Biocept
BIOC
|
22 M | - | -13.05 % | $ 7.29 M | USA |
 |
Interpace Biosciences
IDXG
|
11.5 M | $ 1.67 | -6.7 % | $ 7.39 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
21.6 M | - | - | $ 562 M |  Britain |
 |
Illumina
ILMN
|
2.7 B | $ 162.32 | -3.42 % | $ 25.2 B | USA |
 |
CareDx, Inc
CDNA
|
110 M | $ 22.25 | -3.76 % | $ 1.19 B | USA |
 |
Chembio Diagnostics
CEMI
|
44.8 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
1.83 M | - | - | $ 9.42 M |  Israel |
 |
ICON Public Limited Company
ICLR
|
7.08 B | $ 149.45 | -2.19 % | $ 11.7 B |  Irlanda |
 |
HTG Molecular Diagnostics
HTGM
|
12.4 M | - | -20.0 % | $ 1.06 M | USA |
 |
Lantheus Holdings
LNTH
|
1.14 B | $ 100.98 | -1.79 % | $ 6.82 B | USA |
 |
Global Cord Blood Corporation
CO
|
3.65 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
186 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
4.36 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
427 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
64.8 M | - | -11.32 % | $ 2.94 M | USA |
 |
NeoGenomics
NEO
|
523 M | $ 10.9 | -3.63 % | $ 1.4 B | USA |
 |
Natera
NTRA
|
686 M | $ 215.31 | -3.06 % | $ 29.4 B | USA |
 |
Charles River Laboratories International
CRL
|
3.92 B | $ 181.34 | -2.4 % | $ 8.99 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
2.7 B | - | - | $ 10.7 B | USA |
 |
Pacific Biosciences of California
PACB
|
779 M | $ 1.45 | -11.04 % | $ 435 M | USA |
 |
Medpace Holdings
MEDP
|
1.52 B | $ 454.25 | -0.97 % | $ 13.1 B | USA |
 |
Mettler-Toledo International
MTD
|
3.74 B | $ 1 154.33 | -2.22 % | $ 23.8 B |  Schweiz |
 |
Exact Sciences Corporation
EXAS
|
3.46 B | - | - | $ 19.8 B | USA |
 |
Myriad Genetics
MYGN
|
339 M | $ 4.57 | -2.56 % | $ 423 M | USA |
 |
National Research Corporation
NRC
|
121 M | $ 19.14 | -3.09 % | $ 428 M | USA |
 |
Personalis
PSNL
|
73 M | $ 10.75 | -11.16 % | $ 959 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
16 B | $ 26.11 | 0.46 % | $ 24.8 B |  Niderland |
 |
Senseonics Holdings
SENS
|
65.2 M | $ 6.67 | -4.85 % | $ 278 M | USA |
 |
QIAGEN N.V.
QGEN
|
3.11 B | - | - | $ 10.6 B | Niderland |
 |
Soleno Therapeutics
SLNO
|
114 M | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
1.84 M | $ 2.12 | -1.17 % | $ 4.87 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
9.76 B | $ 265.15 | 1.6 % | $ 22.1 B | USA |
 |
Twist Bioscience Corporation
TWST
|
169 M | $ 69.22 | -6.37 % | $ 4.14 B | USA |
 |
Thermo Fisher Scientific
TMO
|
28.7 B | $ 472.8 | -1.91 % | $ 178 B | USA |
 |
Trinity Biotech plc
TRIB
|
138 M | $ 0.67 | -2.43 % | $ 241 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
4.54 M | - | -34.28 % | $ 263 K | Israel |
 |
Waters Corporation
WAT
|
2.52 B | $ 365.36 | -2.95 % | $ 21.8 B | USA |
 |
Neogen Corporation
NEOG
|
1.37 B | $ 8.9 | -2.41 % | $ 1.93 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
7.16 B | $ 200.29 | 2.13 % | $ 22.2 B | USA |